Die Psoriasis-Krankheitskosten korrelieren mit der Schwere des klinischen Befundes und nicht mit der psychischen Krankheitslast

Cost‐effectiveness of psoriasis therapy with etanercept in Germany

“…In a recent health services research study [23] 18.5% of patients received topical treatment only, even though systemic treatment was indicated. For this reason, etanercept was compared with topical treatment.…”

“…At least the data on costs come from a German population whose demographic and disease‐specific (e.g. PASI) features generally corresponded to that of the clinical trial population [23].…”

“…The probabilities of transition of the Markov model, the probabilities of side effects as well as the QALY gained by treatment with etanercept and basal therapy were taken over from the British model. In addition, the model was modified to take specific cost structures in the German health care system into account on the basis of a recent health services research study [23]; essential results of this study are in line with those of comparable studies in Germany [12, 13].…”

“…The health services research study [23] was planned as a cost-of-illness analysis out of the perspective of health insurance. The estimation of outpatient physician's cost was based on the Uniform Value Scale (EBM) for patients with statutory health insurance (89 %) and on allowed fees according to the fee schedule for physicians (GOÄ) for patients with private insurance (11 %) [25].…”

“…The amount within the threshold length of stay (3-25 days) is 5,162 € (assumed basal case value 2,900 €, valuation ratio 1.78). In the health services research study the average length of stay for patients with PASI > 70 and DLQI > 20 was 29.75 days [23]. For this group of patients costs of 6.140 €/case for a hospital stay were determined due to the surcharges for excessive length of stay.…”